

**Amendments to the Claims**

Please amend claim 15 as indicated in the listing of claims.

The listing of claims will replace all prior versions, and listings of claims in the application.

**Listing of Claims:**

1.-14. (Canceled).

15. (Currently amended) An isolated antibody that specifically binds to a C-terminal fragment of connective tissue growth factor (CTGF) polypeptide, but not platelet derived growth factor (PDGF), wherein the antibody inhibits DNA synthesis but does not inhibit collagen synthesis, and wherein the C-terminal fragment of CTGF is consists of amino acid residues 4 through 74 of SEQ ID NO:4 or 75 through 172 of SEQ ID NO:4.

16.-18. (Canceled).

19. (Original) The antibody of claim 15, wherein the antibody is a monoclonal antibody.

20. (Original) The antibody of claim 19, wherein the antibody is a human monoclonal antibody.

21. (Original) The antibody of claim 15, wherein the antibody is a polyclonal antibody.

In re Application of:  
Grotendorst and Neff  
Application No.: 10/658,856  
Filed: September 9, 2003  
Page 5 of 11

PATENT  
Atty Docket No.: FIBRO1130-3

22. (Previously presented) The antibody of claim 15, wherein the antibody is a murine antibody.

23. (Original) A composition comprising the antibody of claim 15 and a pharmaceutically acceptable excipient or carrier.

24.-36. (Canceled).

37. (Previously presented) The antibody of claim 15, wherein the antibody is a humanized antibody.